We are doing this study to evaluate the safety and effectiveness of an experimental procedure using new technology called Exablate Model 4000 Type 2.0/2.1 for adults with glioblastoma brain tumors. We want to know what effects it has (good and bad) on biomarkers (an indicator of a condition or disease in the body) released into the bloodstream.

Glioblastoma Multiforme

Adults ages 18-80 who:

• Have a stereotactically-targetable suspected glioblastoma tumor on pre-operative brain imaging scans
• Do NOT have a tumor originating from the deep midline, thalamus, midbrain, cerebellum, or brainstem

For more information about who can be in this study, please contact the study team at 919-684-5301.

The study consists of a screening visit (up to 28 days prior to treatment), a single treatment visit, a 12-48 hour safety check, and a 4 week post-treatment follow up visit.

If you choose to join the study, you will:

• Have physical exams
• Have blood draws
• Have imaging scans (CT and MRI)
• Donate tissue from your standard of care surgical resection or biopsy to be analyzed and compared with the biomarkers detected in your blood samples